Piramal Pharma Limited, established in March 2020, is a public limited company with a global presence in over 100 countries. The company specializes in integrated Contract Development and Manufacturing Organization (CDMO) services, Consumer Healthcare (CHG), and India Consumer Healthcare (ICH) businesses, offering a comprehensive range of pharmaceutical products and services. It operates 17 manufacturing facilities across India, the US, the UK, and Canada. Key offerings include highly potent APIs, antibody drug conjugates, sterile injectables, and biologics.
Piramal Pharma holds a significant joint venture with Allergan (now AbbVie) in the Indian ophthalmology market and has a minority stake in Yapan Bio, which focuses on biologics and vaccines. The company acquired businesses such as Convergence Chemicals and Hemmo Pharmaceuticals to bolster its capabilities. It was listed on the BSE and NSE in October 2022, following a demerger from Piramal Enterprises Limited. In FY 2023, Piramal Pharma launched 26 new products and introduced 37 new SKUs, demonstrating robust growth and innovation.
